Further beyond molecular targets, ISO- and CVS-induced osteoclastogenesis can be therapeutically suppressed by clinically relevant drugs, RANK-Fc and clodronate, which were sufficient to ameliorate ISO- and CVS-induced osteopenias despite the not rescued osteoblastic bone formation rates. Here, TNFRSF11A is linked to Osteopenia.